<DOC>
	<DOCNO>NCT00334477</DOCNO>
	<brief_summary>The purpose study check safety efficacy pde5 inhibitor , tadalafil , special group patient : Renal chronic patient hemodialysis treatment .</brief_summary>
	<brief_title>Efficacy Safety Tadalafil Hemodialysis Patients</brief_title>
	<detailed_description>In country , number patient hemodialysis treatment renal chronic dysfunction huge . As know group great prevalence sexual dysfunction general population , among dysfunction erectile disfunction ( ED ) occupy maybe important position . With advent increase age nation´s population small number organ donation , number men suffer ED hemodialysis surely significant cause important problem health system . Up there´s little indexed publication support use tadalafil special group men . Another PDE 5 inhibitor , sildenafil , use patient success safety obviously need option efficacy . We intend study give u background treat ED already unfortunate one .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Men 18 70 year old Diagnosticated ED 6 month least Accept protocol Sign inform consent Renal chronic patient hemodyalisis History another PDE5 inhibittor use . C.C.I . grade III ( NYHA )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>erectile dysfunction</keyword>
	<keyword>chronic renal dysfunction</keyword>
	<keyword>tadalafil</keyword>
</DOC>